Myomo (MYO) Investor presentation summary

Market opportunity and patient need

• 800,000 new stroke cases annually in the US, with 50–60% left with upper limb impairment.

• 3.8 million Americans live with upper extremity impairment post-stroke.

• 400,000 to 800,000 patients may qualify for the MyoPro device, depending on insurance and medical criteria.

• 40,000 to 80,000 patients replenish the prevalence population each year.

Product and technology

• MyoPro arm brace enables daily activities for those with upper limb paralysis.

• Uses proprietary brain-computer interface and EMG signal amplification.

• 35 patents valid through 2042 protect the technology.

• Non-invasive sensing and patient’s brain act as the controller.

Business model and growth strategy

• Three distribution channels: direct-to-patient, rehab hospital referrals, and orthotics/prosthetics clinics.

• Focus on recurring patient sources and expanding payer contracts to increase market access.

• Medicare reimbursement and new payer contracts are expanding patient access.

• Investing in product development and research to support growth.